MDMA and 5‐HT neurotoxicity: the empirical evidence for its adverse effects in humans – no need for translation
British Journal of Pharmacology March 9, 2012 DOI: 10.1111/j.1476-5381.2012.01941.x (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Commentary Peer reviewed |
|---|---|
| Population | Abstinent recreational ecstasy/MDMA users |
| Topics | MDMA |
| Keywords | Neurotoxicity Adverse effect Translation biology Pharmacology |
| Citations | 50 |
| Key points | Argues that MDMA is clearly damaging to humans, with extensive empirical data for both structural and functional deficits, including reduced SERT levels and correlated neurocognitive impairments. |
Abstract
In this issue of the BJP , Green et al . suggest that animal data could not be used to predict the adverse effects of 3,4‐methylenedioxymethamphetamine (MDMA) in humans and that MDMA did not produce 5‐HT neurotoxicity in the human brain. This proposal was, however, not accompanied by a review of the empirical evidence in humans. The neuroimaging data on 5‐HT markers in abstinent recreational ecstasy/MDMA users are extensive and broadly consistent. Reduced levels of the 5‐HT transporter (SERT) have been found by research groups worldwide using a variety of assessment measures. These SERT reductions occur across the higher brain regions and remain after controlling for potential confounds. There are also extensive empirical data for impairments in memory and higher cognition, with the neurocognitive deficits correlating with the extent of SERT loss. Hence, MDMA is clearly damaging to humans, with extensive empirical data for both structural and functional deficits. LINKED ARTICLES This article is a commentary on Green et al ., pp. 1523–1536 of this issue. To view this paper visit http://dx.doi.org/10.1111/j.1476‐5381.2011.01819.x . A rebuttal by Green et al . also appears in this issue, pp. 1521–1522. To view this rebuttal visit http://dx.doi.org/10.1111/j.1476‐5381.2012.01940.x
Citations in the library
Cited by 21
- Human psychobiology of MDMA or ‘Ecstasy’: an overview of 25 years of empirical research Human Psychopharmacology: Clinical and Experimental July 1, 2013
- Legal highs: staying on top of the flood of novel psychoactive substances Therapeutic Advances in Psychopharmacology January 26, 2015
- Serotonin toxicity of serotonergic psychedelics Psychopharmacology July 12, 2021
- Effects of Acute MDMA Intoxication on Mood and Impulsivity: Role of the 5-HT2 and 5-HT1 Receptors PLoS One July 10, 2012
- The preclinical pharmacology of mephedrone; not justMDMAby another name British Journal of Pharmacology March 24, 2014
and 16 more in the library
Cites 12
- Amphetamine toxicities Annals of the New York Academy of Sciences January 8, 2010
- Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[11C]DASB and structural brain imaging study Brain May 17, 2010
- Ecstasy/MDMA attributed problems reported by novice, moderate and heavy recreational users Human Psychopharmacology: Clinical and Experimental July 12, 2002
- MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress Journal of Psychopharmacology March 1, 2006
- In Vivo Imaging of Cerebral Serotonin Transporter and Serotonin2A Receptor Binding in 3,4-Methylenedioxymethamphetamine (MDMA or “Ecstasy”) and Hallucinogen Users Archives of General Psychiatry June 6, 2011
and 7 more in the library